Company Description
Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases.
Its lead product candidate is ixoberogene soroparvovec Ixo-vec, a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials.
The company is developing BGTF-027 (AAV.7m8-L-opsin), a novel gene therapy product candidate designed to deliver a functional copy of the OPN1LW gene to the foveal cones of patients suffering from blue cone monochromacy.
Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Ray Therapeutics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016.
Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
| Country | United States |
| Founded | 2006 |
| IPO Date | Jul 31, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 155 |
| CEO | Laurent Fischer |
Contact Details
Address: 100 Cardinal Way Redwood City, California 94063 United States | |
| Phone | 650 656 9323 |
| Website | adverum.com |
Stock Details
| Ticker Symbol | ADVM |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001501756 |
| CUSIP Number | 00773U108 |
| ISIN Number | US00773U1088 |
| Employer ID | 20-5258327 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Laurent Fischer | President, Chief Executive Officer and Director |
| Linda M. Rubinstein M.A. | Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer |
| Kishor Peter Soparkar J.D. | Chief Operating Officer |
| Dr. Setareh Seyedkazemi Pharm.D. | Chief Development Officer |
| Dr. Rabia Gurses Ozden M.D. | Chief Medical Officer |
| Dr. R. Andrew Ramelmeier Ph.D. | Chief Technology Officer |
| Dr. Romuald Corbau Ph.D. | Chief Scientific Officer |
| Aneta Ferguson | General Counsel |
| Dena House | Chief People Officer |
| Carla Fiankan | Senior Vice President of Regulatory Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 23, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 20, 2025 | SCHEDULE 13D | Filing |
| May 15, 2025 | SCHEDULE 13G/A | Filing |
| May 14, 2025 | 10-Q | Quarterly Report |
| May 14, 2025 | 8-K | Current Report |
| May 6, 2025 | SCHEDULE 13G/A | Filing |
| Apr 28, 2025 | ARS | Filing |
| Apr 28, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 28, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 18, 2025 | PRE 14A | Other preliminary proxy statements |